A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian cancer. A chemotherapeutic assay (ChemoID) designed to to select targeted ...

The development of antibody-drug conjugates (ADCs) remains a central theme in ongoing research within the realm of ovarian cancer, and work examining different targets and sequencing considerations ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment paradigms in ovarian cancer. Potential practice-changing therapies in ...